These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1985171)

  • 1. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia.
    Martínez JA; Martín G; Sanz GF; Sempere A; Jarque I; de la Rubia J; Sanz MA
    J Clin Oncol; 1991 Jan; 9(1):39-43. PubMed ID: 1985171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia.
    Sanz MA; Sanz GF; Martínez JA; Senent L; López F; Palau J; Martín G; Jarque I
    Ann Oncol; 1992 Aug; 3 Suppl 3():39-42. PubMed ID: 1390315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses.
    Meyers FJ; Welborn J; Lewis JP; Flynn N
    J Clin Oncol; 1989 Feb; 7(2):173-8. PubMed ID: 2644396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose carboplatin in the treatment of hematologic malignancies.
    Vogler WR
    Oncology; 1993 Nov; 50 Suppl 2():42-6. PubMed ID: 8233301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial.
    Welborn JL; Kopecky KJ; Meyers FJ; Veith R; Shurafa M; Doroshow JH; Balcerzak SP; Appelbaum FR
    Leukemia; 1995 Jul; 9(7):1126-9. PubMed ID: 7630183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
    Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
    Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of carboplatin in relapsed and refractory leukemia.
    Vogler WR; Harrington DP; Winton EF; Lazarus HM; Bennett JM; Cassileth PA; Oken MM
    Leukemia; 1992 Oct; 6(10):1072-5. PubMed ID: 1405761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia.
    Letendre L; Noel P; Tefferi A; Solberg LA; Gastineau DA; Hoagland HC
    Am J Clin Oncol; 1995 Oct; 18(5):382-4. PubMed ID: 7572751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.
    Sadowitz PD; Dubowy R; Souid A; Pollock BH; Weinstein H; Parmley RT; Bowman WP; Land V; Vats T; Pratt C
    J Clin Oncol; 1994 Sep; 12(9):1969-73. PubMed ID: 8083718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
    Kritz AD; Raptis G; Menendez-Botet C; Maslak P; Jakubowski A
    Am J Hematol; 1996 Feb; 51(2):117-21. PubMed ID: 8579051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
    Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
    J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S; Baker M; Bhalla K
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly.
    Archimbaud E; Anglaret B; Thomas X; Devaux Y; Ffrench M; Sebban C; Troncy J; Fiere D
    Leukemia; 1992 Aug; 6(8):776-9. PubMed ID: 1640728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of a new cisplatin derivative for hematologic malignancies.
    Tamura K; Makino S; Araki Y
    Cancer; 1990 Nov; 66(10):2059-63. PubMed ID: 2224759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.